VENICE, ITALY--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of updated clinical data on ZIO-201 at the Connective Tissue Oncology Society (CTOS) meeting in Venice. Related new preclinical data for ZIO-201 was the subject of an earlier presentation at CTOS. ZIO-201 is a proprietary form of the therapeutic active metabolite of ifosfamide (IFOS), a drug that is the standard of care in the treatment of sarcoma and is widely used in the treatment of lymphoma and pediatric cancers. IFOS is associated with severe toxicity to the bladder and the central nervous system because of the presence of two other metabolites – acrolein and chloroacetaldehyde. These toxicities can be particularly troubling, especially in the treatment of pediatric cancers.
